ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.

3 brokerages have issued 12 month target prices for ANI Pharmaceuticals' shares. Their ANIP share price targets range from $70.00 to $73.00. On average, they expect the company's share price to reach $71.67 in the next year. This suggests a possible upside of 43.4% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.

ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of 2023. Since then, ANIP stock has increased by 24.2% and is now trading at $49.96.
View the best growth stocks for 2023 here.

ANI Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 376,800 shares, a decline of 11.0% from the October 31st total of 423,400 shares. Based on an average trading volume of 174,100 shares, the days-to-cover ratio is currently 2.2 days.
View ANI Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ANIP earnings forecast.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, topping the consensus estimate of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to the consensus estimate of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. ANI Pharmaceuticals's quarterly revenue was up 57.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.46 earnings per share.

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

ANI Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, October, 5th. The company provided earnings per share (EPS) guidance of $3.62-$4.11 for the period, compared to the consensus EPS estimate of $3.97. The company issued revenue guidance of $425.00 million-$445.00 million, compared to the consensus revenue estimate of $442.97 million.

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Global Alpha Capital Management Ltd. (2.59%), William Blair Investment Management LLC (2.46%), Ranger Investment Management L.P. (2.10%), Invesco Ltd. (1.67%), AIGH Capital Management LLC (1.34%) and Ameriprise Financial Inc. (1.22%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.